Back to Search Start Over

Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma

Authors :
Michelle Mierzwa
Jie Su
Fabio Y. Moraes
Andrew Hope
John Waldron
J. Lukovic
Jolie Ringash
Scott V. Bratman
Gustavo Nader Marta
Shao Hui Huang
Wei Xu
David P. Goldstein
John Kim
Ali Hosni
M.E. Spector
Luiz Paulo Kowalski
Andrew J. Rosko
Brian O'Sullivan
John R. de Almeida
Fatima Alfaraj
Source :
Journal of Clinical Oncology. 37:6085-6085
Publication Year :
2019
Publisher :
American Society of Clinical Oncology (ASCO), 2019.

Abstract

6085 Background: We developed and validated a prediction-score for distant metastases (DM) in major salivary gland carcinoma (SGC). Methods: Patients with SGC treated with curative-intent surgery +/- postoperative radiation therapy (PORT) at 4 tertiary cancer centers were divided into discovery (institution A&B) and validation (institution C&D) cohorts. Multivariable analysis using competing risk regression was used to identify predictors of DM in the discovery cohort and create a prediction score. The optimal score cut-off for high vs low-DM risk was determined using a minimal p-value approach. The results were subsequently evaluated in the validation cohort. The cumulative incidence and Kaplan-Meier methods were used to analyze DM and overall survival (OS), respectively. Results: Overall, 1035 patients were included (Table). In the discovery cohort, DM predictors (risk score coefficient) were: positive margin (0.6), pT3-4 (0.7), pN+ (0.7), lymphovascular invasion (LVI; 0.8), and high risk histology* (1.2). High DM-risk SGC was defined by sum of coefficients greater than 2. In the discovery cohort, the 5-year cumulative incidence of DM for high vs low risk SGC was 50% vs 8%; p < 0.01; these results were similar in the validation cohort (44% vs 4% at 5 years; p < 0.01). In the combined cohorts, this model predicted distant-only failure (40% vs 6%, p < 0.01) and late ( > 2yr post surgery) DM (22% vs 4%; p < 0.01). Patients with high DM-risk SGC had an increased incidence of DM in the subgroup receiving PORT (46% vs 8%; p < 0.01) or concurrent chemotherapy (71% vs 34%; p < 0.01). The 5-yr OS for high vs low risk SGC was 48% vs 92% (p < 0.01). Conclusions: This validated prediction score model may be used to identify SGC patients at increased risk for DM and select those who may benefit from prospective evaluation of treatment intensification and/or surveillance strategies. Baseline characteristics. [Table: see text]

Details

ISSN :
15277755 and 0732183X
Volume :
37
Database :
OpenAIRE
Journal :
Journal of Clinical Oncology
Accession number :
edsair.doi...........64906c9956110aab411f5c76973603fe
Full Text :
https://doi.org/10.1200/jco.2019.37.15_suppl.6085